Metacrine, Inc. MTCR
We take great care to ensure that the data presented and summarized in this overview for Metacrine, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MTCR
View allLatest Institutional Activity in MTCR
Top Purchases
Top Sells
About MTCR
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Insider Transactions at MTCR
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Mar 23
2023
|
Preston Klassen Director |
SELL
Grant, award, or other acquisition
|
Direct |
842,211
-37.83%
|
$0
$0.47 P/Share
|
Jan 26
2023
|
Preston Klassen Director |
SELL
Open market or private sale
|
Direct |
380,605
-41.26%
|
$0
$0.41 P/Share
|
Jan 26
2023
|
Michael York Chief Business Officer |
SELL
Open market or private sale
|
Direct |
107,054
-50.84%
|
$0
$0.41 P/Share
|
Dec 21
2022
|
Braden Michael Leonard > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
120,099
+1.91%
|
$0
$0.4 P/Share
|
Dec 20
2022
|
Braden Michael Leonard > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
50,122
+0.82%
|
$0
$0.38 P/Share
|
Dec 19
2022
|
Braden Michael Leonard > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
101,384
+1.66%
|
$0
$0.4 P/Share
|
Nov 09
2022
|
Braden Michael Leonard > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
39,816
+0.67%
|
$0
$0.39 P/Share
|
Nov 08
2022
|
Braden Michael Leonard > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
500
+0.01%
|
$0
$0.4 P/Share
|
Nov 07
2022
|
Braden Michael Leonard > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
123,954
+2.08%
|
$0
$0.42 P/Share
|
Oct 28
2022
|
Braden Michael Leonard > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
45,022
+0.78%
|
$0
$0.4 P/Share
|
Oct 27
2022
|
Braden Michael Leonard > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
767,507
+11.9%
|
$0
$0.39 P/Share
|
Oct 26
2022
|
Braden Michael Leonard > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
588,533
+10.7%
|
$0
$0.35 P/Share
|
Oct 25
2022
|
Braden Michael Leonard > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
499,279
+10.35%
|
$0
$0.35 P/Share
|
Oct 24
2022
|
Braden Michael Leonard > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
174,354
+4.36%
|
$0
$0.34 P/Share
|
Apr 19
2022
|
Preston Klassen Director |
SELL
Open market or private sale
|
Direct |
44,748
-2.32%
|
$0
$0.51 P/Share
|
Apr 14
2022
|
Preston Klassen Director |
BUY
Grant, award, or other acquisition
|
Direct |
104,500
+9.75%
|
-
|
Feb 27
2022
|
Michael York Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
210,553
+50.0%
|
-
|
Feb 27
2022
|
Preston Klassen Director |
BUY
Grant, award, or other acquisition
|
Direct |
842,211
+49.4%
|
-
|
Dec 22
2021
|
New Enterprise Associates 16, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
459,700
-7.9%
|
$0
$0.96 P/Share
|
Dec 22
2021
|
Forest Baskett > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
459,700
-7.9%
|
$0
$0.96 P/Share
|